Danielle Ternyila

Articles

JAK Inhibitors Build Momentum in Myelofibrosis Treatment

November 24, 2020

With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.

Predicting Immunotherapy Response in Melanoma

November 11, 2020

Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1 Now, investigators are working to answer more questions about this group of patients.

ctDNA Monitoring Is Important for BRAF-Mutant Melanoma

July 27, 2019

Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).

US Cancer Death Rate Drops 27% Over 25 Years

January 16, 2019

The cancer death rate declined 27% in the United States from 1991 to 2016, as reported by the American Cancer Society in its annual report, in part due to the significant decline in smoking and an increase in advances for early cancer detection and screening.